This is an open-label repeat dose, multicenter, 2-part study to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for GSK525762 given once-daily (QD) orally. Part 1 of the study is a dose escalation phase to select the recommended Part 2 dose (RP2D) based on the safety, PK, and PD profiles observed after oral administration of GSK525762. Eligible subjects with select relapsed
A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR) of tipifarnib in approximately 36 eligible subjects with Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPN), including Chronic Myelomonocytic Leukemia (CMML), and 36 eligible subjects with
As a physician–scientist, Dr. Tibes is grateful for the opportunity to advance treatments for people who have cancer through my own groundbreaking research. He has been involved in developing national treatment guidelines for leukemia, and he has been actively engaged in translational research to identify and develop new leukemia treatments over the last few years. Many of these treatments, which directly target the DNA of cancer cells or push leukemia cells to die, were developed in Dr. Tibes' laboratory and have led to clinical trials and U.S. Food and Drug Administration approvals.